Orthocell (OCC) H2 2026 earnings summary

Executive summary

• Achieved record revenue of A$13.2M for FY26, up 45% year-over-year, driven by increased adoption of collagen medical devices in established and new international markets.

• Expanded US commercial footprint for Remplir, with 18 distributors across 20+ states, 70 hospitals purchasing, and 76 surgeons using the product.

• Strengthened financial position with A$44M in available funds and completed a A$30M capital raise.

• Advanced manufacturing expansion and automation to support future growth.

Financial highlights

• Revenue grew to A$13.2M from A$9.1M in FY25 (+45%).

• Gross profit increased to A$6.7M from A$3.6M (+86%).

• Loss after income tax widened to A$13.9M from A$8.6M (+62%).

• Net tangible assets per share rose to A$0.1235 from A$0.0555.

• No dividends declared or paid.

Outlook and guidance

• Focus on deepening US market adoption for Remplir and expanding in established and new international markets.

• Continued investment in manufacturing, regulatory, and product development initiatives.

• Anticipates further revenue growth as market access converts to routine clinical use.